Online at: https://researchtrendsjournal.com
Indexed Journal

ISSN No: 2584-282X
Peer Reviewed Journal

INTERNATIONAL JOURNAL OF TRENDS IN EMERGING RESEARCH AND DEVELOPMENT

Volume 2; Issue 3; 2024; Page No. 271-276

Received: 03-02-2024
Accepted: 16-03-2024

Exploring the Synergistic Effects of MBCT and Pharmacological Interventions for PTSD

[1]Leena M and [2]Dr. Yugal Kishore

[1]Research Scholar, Department of Clinical Psychology, North East Christian University, Dimapur, Nagaland, India
[2]Professor, Department of Clinical Psychology, North East Christian University, Dimapur, Nagaland, India

Corresponding Author: Leena M

Abstract

Post-Traumatic Stress Disorder (PTSD) is a complex mental health condition that often requires multifaceted treatment approaches. While pharmacological interventions such as selective serotonin reuptake inhibitors (SSRIs) remain a first-line treatment, many patients experience only partial relief or relapse upon discontinuation. This study investigates the synergistic effects of combining Mindfulness-Based Cognitive Therapy (MBCT) with standard pharmacotherapy in individuals diagnosed with PTSD. A randomized controlled trial was conducted with 120 participants divided into three groups: pharmacotherapy only, MBCT only, and a combined treatment group. Quantitative data were collected over 12 weeks using the Clinician-Administered PTSD Scale (CAPS-5), Beck Depression Inventory-II (BDI-II), and Five Facet Mindfulness Questionnaire (FFMQ). Results indicated that the combined treatment group exhibited significantly greater symptom reduction, improved emotional regulation, and increased mindfulness compared to either intervention alone. The findings support an integrative approach, suggesting that MBCT may enhance the therapeutic efficacy of pharmacological treatment by addressing cognitive and emotional dimensions often resistant to medication alone.

Keywords: Post-Traumatic Stress Disorder (PTSD), Mindfulness-Based Cognitive Therapy (MBCT), Pharmacotherapy, Combined Treatment, Emotional Regulation

Introduction

Post-Traumatic Stress Disorder (PTSD) is a chronic and debilitating psychological condition that develops in response to exposure to traumatic events, including but not limited to violence, natural disasters, combat, and personal assault. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), PTSD is characterized by intrusive memories, avoidance behaviors, negative alterations in cognition and mood, and heightened arousal (American Psychiatric Association, 2013) [1]. Globally, PTSD affects approximately 3.9% of the general population and up to 30% of those exposed to severe trauma, such as military personnel and victims of sexual assault (Koenen *et al*., 2017) [10].

Pharmacological interventions have traditionally been the frontline treatment for PTSD, particularly selective serotonin reuptake inhibitors (SSRIs) such as sertraline and paroxetine, both approved by the U.S. Food and Drug Administration (Davidson *et al*., 2001) [4]. However, pharmacotherapy often yields mixed results, with many patients experiencing residual symptoms, relapse upon discontinuation, or adverse side effects that hinder long-term compliance (Hoskins *et al*., 2015) [8]. This limitation has prompted mental health practitioners and researchers to explore adjunctive or integrative approaches to PTSD treatment.

One promising adjunctive modality is Mindfulness-Based Cognitive Therapy (MBCT), a structured, eight-week group program that combines elements of cognitive behavioral therapy with mindfulness meditation practices (Segal, Williams, & Teasdale, 2002) [17]. MBCT was originally developed to prevent relapse in individuals with recurrent depression but has since been adapted for a range of mental health disorders, including PTSD (King *et al*., 2013) [9]. The therapeutic mechanisms of MBCT-such as increased metacognitive awareness, reduced rumination, and

improved emotional regulation-target core PTSD symptoms like hypervigilance, intrusive thoughts, and emotional numbing (Banks *et al*., 2015) [2].

Emerging evidence suggests that MBCT may serve as a powerful complement to pharmacotherapy. While SSRIs modulate neurochemical imbalances associated with PTSD, MBCT works to enhance self-awareness, reframe maladaptive thought patterns, and build psychological resilience (Boyd *et al*., 2018) [3]. Moreover, MBCT may attenuate emotional reactivity and physiological arousal, two domains in which pharmacological treatments often fall short (Polusny *et al*., 2015) [14]. Integrating MBCT into a pharmacological treatment framework could therefore create a synergistic effect, enhancing overall treatment efficacy by addressing both neurobiological and psychological dimensions of PTSD.

Despite the theoretical promise of such an integrative model, empirical studies examining the combined efficacy of MBCT and pharmacotherapy for PTSD remain limited. Most existing studies evaluate these modalities in isolation, leading to a fragmented understanding of their potential complementarity. This study aims to address this research gap by evaluating the synergistic effects of MBCT when used alongside standard pharmacological treatment for PTSD. By employing a randomized controlled design and validated psychometric instruments, the present research seeks to determine whether combined therapy results in superior clinical outcomes compared to either modality alone.

In light of the increasing prevalence of trauma-related disorders and the limitations of mono-modal treatments, it is both timely and necessary to investigate holistic, multi-dimensional interventions that offer sustainable recovery. The integration of MBCT and pharmacotherapy represents a promising direction in the evolving landscape of PTSD treatment, with implications for both clinical practice and future research.

Review of Literature

Post-Traumatic Stress Disorder (PTSD) is a multifaceted psychological condition that often requires a comprehensive treatment approach. The extant literature offers extensive insights into the effectiveness of both pharmacological and psychological interventions. However, integrated approaches-especially those combining Mindfulness-Based Cognitive Therapy (MBCT) with pharmacotherapy-are relatively underexplored. This literature review synthesizes empirical findings on the efficacy of pharmacological treatments, MBCT interventions, and their potential synergy in treating PTSD.

Pharmacological Interventions in PTSD

Pharmacological treatment remains the most widely prescribed approach for managing PTSD, particularly in clinical psychiatry settings. SSRIs such as sertraline and paroxetine are FDA-approved for PTSD and have demonstrated efficacy in reducing core symptoms such as re-experiencing, avoidance, and hyperarousal (Davidson *et al*., 2001) [4]. Additionally, other pharmacological agents such as venlafaxine, mirtazapine, and prazosin have been evaluated for specific symptoms like sleep disturbances and nightmares (Stein *et al*., 2006; Raskind *et al*., 2007) [18, 15].

Despite moderate success, pharmacotherapy often results in partial remission, with dropout rates remaining high due to side effects or lack of perceived benefit (Hoskins *et al*., 2015) [8]. Meta-analyses suggest that approximately 40–60% of patients respond to SSRIs, but fewer than 30% achieve full remission (Lee *et al*., 2016) [13].

Mindfulness-Based Cognitive Therapy and PTSD

MBCT was originally developed for relapse prevention in recurrent depression but has since expanded to anxiety disorders, including PTSD (Segal *et al*., 2002) [17]. Unlike exposure-based therapies, which directly confront trauma memories, MBCT promotes nonjudgmental awareness and acceptance, thereby helping individuals decenter from traumatic thoughts and reduce emotional reactivity (Kuyken *et al*., 2015). MBCT has been shown to improve attentional control and emotion regulation, both of which are impaired in PTSD (Banks *et al*., 2015) [2].

Randomized controlled trials (RCTs) support MBCT's effectiveness in reducing PTSD symptoms across different populations. For example, King *et al*. (2013) [9] reported significant symptom improvement in combat veterans participating in group MBCT sessions. Similarly, Polusny *et al*. (2015) [14] found MBCT to be as effective as Present-Centered Therapy (PCT) in reducing PTSD severity among U.S. veterans. A meta-analysis by Hilton *et al*. (2017) [7] concluded that mindfulness-based interventions result in small to moderate reductions in PTSD symptoms, with MBCT and Mindfulness-Based Stress Reduction (MBSR) showing the greatest promise.

Comparative Studies and Limitations

When compared to other psychological therapies like Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT), MBCT may be more acceptable to patients unwilling to engage in trauma-focused exposure work (Boyd *et al*., 2018) [3]. While PE has robust empirical support, dropout rates are high due to emotional distress triggered by revisiting traumatic memories (Schottenbauer *et al*., 2008) [16]. In contrast, MBCT's non-exposure approach may offer a gentler alternative with fewer adverse emotional effects.

However, MBCT also has limitations. It requires significant time commitment, high levels of cognitive engagement, and is less effective for patients with severe cognitive distortions or dissociation (van der Kolk, 2015) [20]. Additionally, while MBCT improves emotional regulation, it may not adequately address trauma-specific symptoms without supplementary intervention (Lang *et al*., 2012) [12].

Integrated Approaches: Potential Synergy

Given the limitations of mono-modal therapies, integrated treatment models have gained attention. Combining pharmacotherapy with mindfulness-based interventions may yield synergistic benefits by targeting both neurochemical imbalances and maladaptive cognitive-emotional patterns (Boyd *et al*., 2018) [3]. Preliminary studies suggest that mindfulness practices may enhance medication adherence, reduce side-effect sensitivity, and improve overall quality of life (Goyal *et al*., 2014) [6]. Moreover, MBCT may potentiate the neuroplastic effects of SSRIs, further facilitating emotional processing and cognitive restructuring (Tang *et al*., 2015) [19].

Though direct studies on MBCT-pharmacotherapy combinations in PTSD are scarce, analogous research in depression and anxiety provides compelling support. For instance, Godfrin and van Heeringen (2010) [5] found that MBCT combined with antidepressant treatment significantly reduced relapse rates in patients with major depressive disorder. Translating this integrated model to PTSD may similarly improve long-term outcomes and symptom durability.

Research Gaps and Rationale for the Current Study

Despite promising findings, few studies have rigorously examined the efficacy of MBCT combined with pharmacological interventions specifically for PTSD. Existing research often focuses on either modality in isolation, limiting our understanding of their interactive effects. Furthermore, there is a paucity of longitudinal data assessing whether the combined approach produces more sustained symptom relief compared to standalone treatments. This study seeks to fill this empirical gap by systematically evaluating the efficacy of integrated MBCT and pharmacotherapy in a PTSD population, using a randomized controlled trial design.

Research Methodology

This study adopted a quantitative, randomized controlled trial (RCT) design to evaluate the efficacy of an integrated treatment approach combining Mindfulness-Based Cognitive Therapy (MBCT) and pharmacological interventions in managing Post-Traumatic Stress Disorder (PTSD). The methodology was structured to ensure the scientific rigor necessary to assess the potential synergistic effects of these interventions on PTSD symptom reduction.

Participants and Sampling

The participants were selected using purposive sampling from a clinical psychology outpatient unit affiliated with a tertiary care hospital in North India. A total of 90 adult participants, aged between 18 and 55 years, who had been diagnosed with PTSD according to the DSM-5 criteria, were recruited for the study. All participants had experienced trauma at least six months prior to enrollment and had moderate to severe PTSD symptoms as assessed by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Exclusion criteria included current substance use disorders, psychosis, and any neurological impairment. Written informed consent was obtained from all participants prior to enrollment.

Group Allocation and Intervention

Participants were randomly assigned to one of three groups (30 participants each) using a computer-generated randomization sequence:

- Group A received standard pharmacological treatment only (SSRIs, typically sertraline or paroxetine).
- Group B received MBCT sessions without pharmacological treatment.
- Group C received both MBCT and pharmacological treatment concurrently.

The MBCT program followed the standard 8-week protocol developed by Segal, Williams, and Teasdale (2002) [17], delivered in group sessions led by a certified MBCT therapist. Each session lasted for approximately 2 hours and included mindfulness meditation, body scan exercises, cognitive restructuring, and homework assignments. Pharmacological treatment was administered and monitored by a licensed psychiatrist, ensuring dosage consistency and compliance over the study period.

Data Collection Tools

Primary outcome data were collected using the CAPS-5, administered at baseline, after the 8-week intervention, and during a 3-month follow-up. Secondary outcome measures included the PTSD Checklist for DSM-5 (PCL-5), the Beck Depression Inventory-II (BDI-II), and the Mindful Attention Awareness Scale (MAAS) to assess mindfulness levels. Medication adherence was monitored using the Medication Adherence Rating Scale (MARS).

Data Analysis

Data were analyzed using SPSS version 25. Descriptive statistics were used to summarize demographic data. To assess within-group and between-group differences, repeated measures ANOVA and post-hoc Bonferroni tests were applied. Effect sizes were calculated using Cohen's d, and statistical significance was set at $p<0.05$. Missing data were handled using the intention-to-treat approach with multiple imputations for robustness.

Objectives of the Study

1. To evaluate the individual effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) and pharmacological interventions in reducing PTSD symptoms among adult patients.
2. To assess the combined (synergistic) effect of MBCT and pharmacological treatment in improving psychological well-being, emotional regulation, and symptom remission in individuals diagnosed with PTSD.
3. To compare the long-term outcomes (at 3-month follow-up) of MBCT-only, pharmacotherapy-only, and combined intervention groups in terms of PTSD symptom reduction, mindfulness levels, and medication adherence.

Hypotheses of the Study

1. **H_1:** Participants receiving the combined intervention of MBCT and pharmacological treatment will show a significantly greater reduction in PTSD symptoms compared to those receiving either MBCT or pharmacotherapy alone.
2. **H_2:** Participants undergoing MBCT (with or without pharmacotherapy) will demonstrate significantly higher levels of mindfulness and emotional regulation compared to those receiving only pharmacological treatment.
3. **H_3:** The combined intervention group will exhibit better long-term symptom remission and treatment adherence at the 3-month follow-up compared to the MBCT-only and pharmacotherapy-only groups.

Analysis and Interpretation

Hypothesis H_1: Participants receiving the combined

intervention of MBCT and pharmacological treatment will show a significantly greater reduction in PTSD symptoms compared to those receiving either MBCT or pharmacotherapy alone.

To test this hypothesis, PTSD symptom severity was measured using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at three points: pre-intervention (Week 0), post-intervention (Week 8), and follow-up (Week 20). Participants were divided into three groups:

- **Group A:** Pharmacotherapy only
- **Group B:** MBCT only
- **Group C:** Combined MBCT + Pharmacotherapy

A repeated measures ANOVA was used to analyze the within-group and between-group differences in PTSD symptom scores over time. The mean CAPS-5 scores are presented in Table 1 below.

Table 1: Mean CAPS-5 scores Across Groups at Three Time Points (N = 90)

Group	Week 0 (Pre)	Week 8 (Post)	Week 20 (Follow-up)	Mean Reduction (Week 0 to 20)
Group A: Pharmacotherapy	72.4	56.8	53.5	18.9
Group B: MBCT	71.6	52.1	48.7	22.9
Group C: MBCT + Medication	73.2	44.3	39.5	33.7

Statistical Analysis

A repeated measures ANOVA revealed a significant main effect of time (F (2, 174) = 102.84, p<0.001), indicating that PTSD symptoms decreased across all three groups from pre-test to follow-up. Importantly, a significant interaction effect between time and group was found (F(4, 174) = 12.56, p<0.001), suggesting that the pattern of symptom reduction differed by treatment group.

Post-hoc comparisons using the Bonferroni test showed that:

- Group C (combined intervention) had a significantly greater reduction in PTSD symptoms than Group A (mean difference = 14.8, p<0.001) and Group B (mean difference = 10.8, p<0.01).
- The difference between Group A and Group B was also statistically significant (mean difference = 4.0, p = 0.04), but smaller in magnitude.

Effect sizes (Cohen's d) for symptom reduction from baseline to follow-up were

- **Group A:** 0.84 (large effect)
- **Group B:** 1.15 (large effect)
- **Group C:** 1.76 (very large effect)

The analysis supports Hypothesis H_1, indicating that the combined treatment of MBCT and pharmacotherapy produced significantly greater reductions in PTSD symptoms compared to either treatment alone. Participants in the combined group not only experienced the steepest decline in CAPS-5 scores over time but also maintained these improvements at the 3-month follow-up.

The results suggest a synergistic effect, wherein the integration of pharmacological stabilization with mindfulness-based cognitive restructuring facilitates a more robust and sustained recovery from PTSD. This finding aligns with prior research highlighting the complementary roles of neurochemical modulation and cognitive-emotional skills training (Tang *et al*., 2015; Goyal *et al*., 2014) [19, 6].

Hypothesis H_2: Participants undergoing MBCT (with or without pharmacotherapy) will demonstrate significantly higher levels of mindfulness and emotional regulation compared to those receiving only pharmacological treatment.

To assess this hypothesis, two validated psychometric instruments were used

- Mindful Attention Awareness Scale (MAAS) to measure mindfulness.
- Difficulties in Emotion Regulation Scale (DERS) to measure emotional regulation capacity.

Data were collected from participants in all three groups at baseline (Week 0) and post-intervention (Week 8). Higher MAAS scores indicate greater mindfulness, while lower DERS scores indicate better emotional regulation.

Table 2: Mean MAAS and DERS Scores (Pre- and Post-Intervention)

Group	MAAS (Pre)	MAAS (Post)	DERS (Pre)	DERS (Post)
Group A: Pharmacotherapy	3.2	3.6	98.4	88.7
Group B: MBCT	3.1	4.8	97.6	72.3
Group C: MBCT + Medication	3.3	5.1	99.1	68.9

Statistical Analysis

A two-way repeated measures ANOVA was performed for both MAAS and DERS scores to examine the effects of group and time on changes in mindfulness and emotional regulation.

Mindfulness (MAAS)

- **Main effect of time:** F(1, 87) = 65.92, p<0.001
- **Main effect of group:** F(2, 87) = 29.18, p<0.001
- **Interaction effect (group × time):** F(2, 87) = 21.45, p<0.001

Emotional Regulation (DERS)

- **Main effect of time:** F(1, 87) = 77.04, p < 0.001
- **Main effect of group:** F(2, 87) = 33.87, p < 0.001
- **Interaction effect (group × time):** F(2, 87) = 25.36, p<0.001

Post-hoc Bonferroni tests showed that Groups B and C had significantly greater increases in MAAS scores and significantly greater reductions in DERS scores compared to Group A (p < 0.01). No significant difference was found between Group B and Group C on MAAS scores, though Group C showed slightly greater gains in emotional regulation.

Effect sizes (Cohen's d) for post-intervention comparisons with Group A

- **MAAS**
  - Group B vs A = 1.24 (large)
  - Group C vs A = 1.38 (large)
- **DERS**
  - Group B vs A = 1.09 (large)
  - Group C vs A = 1.31 (large)

The findings provide strong support for Hypothesis H_2. Participants who underwent MBCT-either alone or in conjunction with pharmacological treatment-demonstrated significantly higher levels of mindfulness and better emotional regulation than those who received only pharmacological intervention.

The results underscore the psychological and cognitive benefits of MBCT, which appears to enhance present-moment awareness and emotional self-regulation-skills particularly crucial for individuals coping with trauma. Although pharmacotherapy may offer neurochemical stabilization, it is MBCT that seems to foster deeper cognitive-affective restructuring. These results are consistent with existing literature (Hölzel *et al*., 2011) [19], which highlights mindfulness as a mechanism for improving psychological resilience in PTSD.

Hypothesis H_3

The combined intervention group will exhibit better long-term symptom remission and treatment adherence at the 3-month follow-up compared to the MBCT-only and pharmacotherapy-only groups.

To test this hypothesis, two primary outcomes were assessed at the 3-month follow-up (Week 20)

1. Symptom remission – measured using the CAPS-5 total scores.
2. Treatment adherence – evaluated using the Medication Adherence Rating Scale (MARS) for pharmacotherapy and MBCT session attendance rates (percentage of sessions attended).

Table 3: Long-Term Outcomes at 3-Month Follow-up (Week 20)

Group	CAPS-5 Score (Week 20)	% Symptom Remission (CAPS-5 ≤ 20)	Mean MARS Score (0–10)	MBCT Attendance Rate (%)
Group A: Pharmacotherapy	53.5	23.3%	6.8	N/A
Group B: MBCT	48.7	30.0%	N/A	82.4
Group C: MBCT + Medication	39.5	56.7%	8.9	91.3

Statistical analysis

A one-way ANOVA was conducted to assess between-group differences in CAPS-5 scores at the 3-month follow-up:

CAPS-5: $F(2, 87) = 18.72$, $p<0.001$

- **Post-hoc tests (Bonferroni):** Group C showed significantly lower CAPS-5 scores than Groups A ($p<0.001$) and B ($p = 0.004$).

For symptom remission rates, a Chi-square test indicated a significant association between treatment group and remission status:

$\chi^2(2) = 9.67$, $p = 0.008$

For treatment adherence, a Kruskal-Wallis H test was used (due to non-parametric distribution of MARS and attendance data):

- **MARS Score:** $H(2) = 14.22$, $p = 0.001$
- **MBCT Attendance Rate:** $H(1) = 5.36$, $p = 0.021$ (between Groups B and C only)

The results strongly support Hypothesis H_3. Participants in the combined intervention group (Group C) exhibited

- The lowest average PTSD symptoms (CAPS-5 score of 39.5) at the 3-month follow-up,
- The highest symptom remission rate (56.7%), and
- Superior adherence to both medication and MBCT protocols (MARS = 8.9; MBCT attendance = 91.3%).

These findings indicate that integrating MBCT with pharmacological treatment not only enhances short-term improvements but also fosters sustained psychological recovery and higher compliance in the long term. The synergistic impact likely results from pharmacotherapy stabilizing acute symptoms, while MBCT equips individuals with cognitive-emotional tools for self-regulation, relapse prevention, and psychological resilience.

This is consistent with earlier research by King *et al*. (2013) [9] and Polusny *et al*. (2015) [14], which emphasized that multimodal approaches combining medication and mindfulness-based interventions significantly outperform standalone treatments in PTSD recovery and maintenance phases.

Conclusion

The present study investigated the comparative and combined effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) and pharmacological interventions in managing Post-Traumatic Stress Disorder (PTSD) symptoms among adults. The findings clearly demonstrated that while both MBCT and pharmacotherapy independently contributed to significant reductions in PTSD symptoms, the combined intervention produced the most substantial and enduring improvements. Participants who received both treatments not only showed the greatest decline in CAPS-5 scores but also exhibited enhanced mindfulness, emotional regulation, and higher treatment adherence at the 3-month follow-up. These results underscore the synergistic value of integrating cognitive-behavioral and pharmacological strategies, as the combination addresses both the neurochemical and cognitive-affective dimensions of PTSD. The superior outcomes observed in the combined group reinforce the need for a multimodal therapeutic approach, particularly for individuals with chronic or treatment-resistant PTSD. Overall, the study contributes important empirical evidence supporting the integration of MBCT into

conventional treatment frameworks and highlights the potential of such hybrid models in enhancing long-term recovery, reducing relapse risk, and improving the quality of life for individuals living with PTSD.

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; c2013.
2. Banks K, Newman E, Saleem J. An overview of the evidence for mindfulness-based interventions in the treatment of PTSD. Clinical Psychology Review. 2015;40:48–61. https://doi.org/10.1016/j.cpr.2015.05.005
3. Boyd JE, Lanius RA, McKinnon MC, Nicholson AA. Mindfulness-based treatments for posttraumatic stress disorder: A review of the treatment literature and neurobiological evidence. Journal of Psychiatry & Neuroscience. 2018;43(1):7–25. https://doi.org/10.1503/jpn.170021
4. Davidson JRT, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry. 2001;58(5):485–492. https://doi.org/10.1001/archpsyc.58.5.485
5. Godfrin KA, van Heeringen C. The effects of mindfulness-based cognitive therapy on recurrence of depression: A randomized controlled study. Behaviour Research and Therapy. 2010;48(8):840–846. https://doi.org/10.1016/j.brat.2010.05.003
6. Goyal M, Singh S, Sibinga EMS, Gould NF, Rowland-Seymour A, Sharma R, *et al*. Meditation programs for psychological stress and well-being: A systematic review and meta-analysis. JAMA Internal Medicine. 2014;174(3):357–368. https://doi.org/10.1001/jamainternmed.2013.13018
7. Hilton L, Maher AR, Colaiaco B, Apaydin E, Sorbero ME, Booth M, *et al*. Mindfulness meditation for posttraumatic stress: Systematic review and meta-analysis. Psychological Trauma: Theory, Research, Practice, and Policy. 2017;9(4):453–460. https://doi.org/10.1037/tra0000180
8. Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, *et al*. Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. The British Journal of Psychiatry. 2015;206(2):93–100. https://doi.org/10.1192/bjp.bp.114.148551
9. King AP, Erickson TM, Giardino ND, Favorite T, Rauch SAM, Robinson E, *et al*. A pilot study of group mindfulness-based cognitive therapy (MBCT) for combat veterans with posttraumatic stress disorder (PTSD). Depression and Anxiety. 2013;30(7):638–645. https://doi.org/10.1002/da.22104
10. Koenen KC, Ratanatharathorn A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, *et al*. Posttraumatic stress disorder in the World Mental Health Surveys. Psychological Medicine. 2017;47(13):2260–2274. https://doi.org/10.1017/S0033291717000708
11. Kuyken W, Warren F, Taylor RS, Whalley B, Crane C, Bondolfi G, *et al*. Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse: An individual patient data meta-analysis from randomized trials. JAMA Psychiatry. 2016;73(6):565–574. https://doi.org/10.1001/jamapsychiatry.2016.0076
12. Lang AJ, Strauss JL, Bomyea J, Bormann JE, Hickman SD, Good RC, *et al*. The theoretical and empirical basis for meditation as an intervention for PTSD. Behavior Modification. 2012;36(6):759–786. https://doi.org/10.1177/0145445512459892
13. Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: Systematic review and meta-analyses to determine first-line treatments. Depression and Anxiety. 2016;33(9):792–806. https://doi.org/10.1002/da.22483
14. Polusny MA, Erbes CR, Thuras P, Moran A, Lamberty GJ, Collins RC, *et al*. Mindfulness-based stress reduction for posttraumatic stress disorder among veterans: A randomized clinical trial. JAMA. 2015;314(5):456–465. https://doi.org/10.1001/jama.2015.8361
15. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, *et al*. A parallel group placebo-controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biological Psychiatry. 2007;61(8):928–934. https://doi.org/10.1016/j.biopsych.2006.06.032
16. Schottenbauer MA, Glass CR, Arnkoff DB, Tendick V, Gray SH. Nonresponse and dropout rates in outcome studies on PTSD: Review and methodological considerations. Psychiatry. 2008;71(2):134–168. https://doi.org/10.1521/psyc.2008.71.2.134
17. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse. New York: Guilford Press; c2002.
18. Stein DJ, Ipser JC, Seedat S, Sager C, Amos T. Pharmacotherapy for post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews. 2006;(1):CD002795. https://doi.org/10.1002/14651858.CD002795.pub2
19. Tang YY, Hölzel BK, Posner MI. The neuroscience of mindfulness meditation. Nature Reviews Neuroscience. 2015;16(4):213–225. https://doi.org/10.1038/nrn3916
20. van der Kolk BA. The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma. New York: Viking; c2015.